reports
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease ...
FREMONT, Calif.--(BUSINESS WIRE)-- presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia. These drug candidates could become the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of vision loss. “Our oral development candidate has the potential to redefine how DME is treated,” said Dr. Anirban Datta, Verseon’s Senior Director of Discovery Biology. “Not only could it replace inconvenie...
Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Cou...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injections, the current standard of care for millions of diabetics at risk of losing their eye sight. Diabetic macular edema (DME) is a leading cause of adult blindness, affecting about one in three long-term diabetes patients. Wi...
Verseon Pioneers New Way of Funding Innovation Through Security Token ...
FREMONT, Calif.--(BUSINESS WIRE)-- is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its STO available to investors around the globe, Verseon will use the technology and services of its subsidiary Using its innovative, computationally driven drug discovery platform, clinical-stage pharmaceutical company Verseon has built a rapidly growing pipeline of unique drug candidates across multiple disease areas. ...
Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding a...
FREMONT, Calif.--(BUSINESS WIRE)-- Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s in Honolulu, HI. The new drug candidates, products of Verseon’s computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease. Millions of patients worldwide could benefit from safe, long-term therapy combining an oral...
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral An...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon’s phase 1 trial in healthy volunteers, which started dosing last week, could lead to a new treatment standard for millions of cardiac patients who would benefit from long-term therapy with both antiplatelet and anticoagulant drugs. Current anticoagulants (NOACs, novel oral anticoagulants) substantially increase major bleeding events, a potentially fatal side effect, especially when they are administered together with antiplatelet drugs. Preclinical studies found that Verseon’s PROACs...
Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-19...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon, a technology-based pharmaceutical company, today announces that it has received ethics committee approval and acknowledgement from the Therapeutic Goods Administration in Australia for the phase I clinical trial of VE-1902, the first clinical candidate from its novel class of precision oral anticoagulants (PROACs). Verseon’s PROACs, in preclinical testing, show a unique combination of efficacy with low bleeding, potentially making them suitable for stroke prevention in atrial fibrillation or...
Verseon Presents New Data on its Precision Oral Anticoagulants at BIO ...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented new preclinical data on its novel class of precision oral anticoagulants (PROACs) at last week’s BIO International Convention in Boston. Verseon’s PROACs demonstrate a unique combination of efficacy with lower bleeding in preclinical testing. This suggests that PROACs may be uniquely positioned to address a significant need for prolonged combination therapy with antiplatelet drugs. Millions of patients worldwide could benefit from safe long-term co-dosing of a...
Verseon Presents Second Anticoagulation Candidate for Clinical Trials ...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented preclinical data on its second anticoagulant candidate, VE-2851, at this week’s American Heart Association conference (Scientific Sessions 2017). VE-2851 shows excellent efficacy paired with low bleeding risk in preclinical testing and is expected to enter clinical trials in 2018. The preclinical data, presented by Verseon’s Director of Discovery Biology Dr. Anirban Datta, shows that VE-2851 potently inhibits thrombin and is highly selective against a panel of relate...
Verseon to Present Preclinical Data on Novel Anticancer Candidates for...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon will present preclinical data on its novel anticancer drug candidates, which have shown promising results in preliminary testing against tumor cell lines resistant to major chemotherapy agents. The results will be shown at the BIO-Europe conference held in Berlin from November 6–8, 2017. Cancer still remains a primary concern with almost 1.7 million people in the US newly diagnosed with some form of cancer in 2016. Currently, chemotherapy is essential to the treatment of most cancers...
Leading pharmaceutical executive Dr. Robert Karr joins Verseon’s Boa...
FREMONT, Calif.--(BUSINESS WIRE)-- Leading pharmaceutical executive and biotech entrepreneur Dr. Robert W. Karr was recently elected as a Non-Executive Director of Verseon, a California-based pharmaceutical company. Dr. Karr had been a member of Verseon’s Scientific Advisory Board, and has helped shape Verseon’s four drug programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. Dr. Karr’s considerable experience across the drug discovery and development process (discovery, preclinical and clinical), as...
Verseon Developing Oral Treatment for Hereditary Angioedema
FREEMONT, Calif.--(BUSINESS WIRE)-- Verseon has announced the launch of a drug program developing oral treatments for hereditary angioedema (HAE), a rare, life-threatening genetic disease. In their interim report published yesterday, the Company presented data from a well-established HAE disease model which demonstrate the efficacy of their plasma kallikrein inhibitors in reducing swelling. HAE is a rare genetic condition affecting approximately 1 in every 50,000 people. The disease is caused by low levels or improper functio...
Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Dia...
FREMONT, Calif.--(BUSINESS WIRE)-- Verseon presented preclinical data on multiple novel drug candidates for the treatment of diabetic macular edema (DME) at the 2017 BIO International Conference in San Diego, last week. Diabetic macular edema is the leading cause of blindness in the diabetic population according to the National Institutes of Health.1 This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170626005666/en/ Left to right: normal vision; blurred vision due to DME;...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.